The document is Bruker Corporation's presentation for investors. It summarizes that Bruker drives profitable growth through enabling scientific discoveries that improve life. It focuses on four strategic growth areas: life science research, applied markets/pharma, nano-analysis/materials research, and clinical/diagnostic markets. Bruker has transitioned from a transformation phase to focusing on operational excellence through initiatives like outsourcing and improving efficiency. Despite currency headwinds, Bruker has improved profitability and free cash flow in recent years.

1. © Bruker Corporation
Bruker drives profitable growth by enabling
breakthrough discoveries & development of new
applications that improve the quality of human life
Innovation with Integrity

2. BRUKER CORPORATION
Safe Harbor Statement
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from
those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global
economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future,
changing technologies, product development and market acceptance of our products, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our
filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our
filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2014, our most
recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law.
© Bruker Corporation 2

3. © Bruker Corporation
Key Messages in 2016
1 Bruker is a differentiated leader
in attractive life science and
diagnostics tools markets, and
our brand stands for innovation
2 We focus on profitable growth in
four strategic growth areas
3 We will drive margin expansion
and cash flow as we transition
from Transformation to our next
phase of Operational Excellence
3

4. © Bruker Corporation
1. Company Overview
2. Profitable Growth Strategy
3. From Transformation to Operational Excellence
4. Financial Overview
Agenda
4

5. © Bruker Corporation
Bruker’s high-performance scientific instruments and high-value
analytical and diagnostic solutions enable our customers to explore
life and materials at …
Microscopic
and Nano-Scales
Cellular and
Sub-Cellular Levels
Small Molecule and
Protein Levels
5

6. © Bruker Corporation
Bruker overview:
• FY2015E revenue ~$1.6 billion
• ~10% R&D investment
• ~75% of revenues from scientific
and diagnostic instrumentation
• ~6,000 employees worldwide
• Going from Transformation to
Operational Excellence phase
• Stable and profitable growth
oriented ownership:
- Founded more than 55 years ago
- RoIC & shareholder value focus
- ~35% of company owned by insiders
41%
26%
4%
29%Americas
Europe
Rest of World
Asia Pacific
Percentage of revenue*:
*as of Q3-15 YTD
6

7. © Bruker Corporation
Bruker is organized in three key Groups:
Bruker BioSpin Group
- NMR/EPR for Research & Pharma
- Applied, Industrial & Clinical MR
- Preclinical Imaging
- Services & Life-Cycle Support
Bruker NANO Group
- Atomic Force Microscopy
- Fluorescence Microscopy for
 Cell Biology & Neurosciences
- X-Ray for Materials Research, QC
- Next-Gen Semicon Metrology
Bruker CALID Group
- Mass Spectrometry for
 Proteomics & Metabolomics
 Applied & Pharma
 Clinical Microbiology, IVD
- FTIR/Raman for Applied Markets
- CBRNE Detection for Security
~$450m* in Revenue~$550m* in Revenue ~$480m* in Revenue
*FY 2015 estimates 7

8. © Bruker Corporation
Bruker serves large markets & a global customer base
Key Markets Largest Customer Segments
Nuclear Magnetic
Resonance
25%
Mass
Spectrometry
18%
X-Ray
13%
Atomic Force
Microscopy
10%
Optical
Spectroscopy
10%
Diagnostics
7%
Pre-Clinical
Imaging
7%
Other
10%
Academic & Government
Industrial
Pharma/Biopharmaceutical
Diagnostic Labs/Hospitals
Applied Markets
8

9. NMR/EPR &
Metabolomics
Preclinical
Imaging &
MALDI Imaging
MALDI ID in
Microbiology
Atomic Force
Microscopy
FT-IR/NIR
X-Ray Diffraction
X-ray Metrology
#1 or #2 market position for:
© Bruker Corporation
Bruker has leading market positions for more than
60% of our product portfolio
9

10. © Bruker Corporation
1. Company Overview
2. Profitable Growth Strategy
3. From Transformation to Operational Excellence
4. Financial Overview
Agenda
10

11. © Bruker Corporation
We are investing in four strategic areas that have attractive
growth and defensible, high-margin opportunities
Life Science
Molecular
Research
Applied
Markets &
Pharma
Nano-Analysis,
Microscopy &
Materials Research
Clinical Research,
Microbiology &
Diagnostics
11

12. © Bruker Corporation
Life Science Molecular Research
EXAMPLE:
Intrinsically Disordered Proteins (IDPs)
• IPDs turn out to be prevalent in nature, and play
many key roles in molecular and cell biology, but are
difficult to analyze (www.darkproteome.org)
• IDPs are abundant in cancer, neurodegenerative
diseases, CVD/diabetes, viral diseases and their
pathogenic functions are not yet well understood
• Ultra-high field NMR is the key technology to study
the biological function of IDPs, and may be key to
unravelling Alzheimer, Parkinson, etc. pathogenesis
12

13. EXAMPLE:
Food/Beverage Safety & Authenticity
• Bruker NMR, MS and IR/NIR instruments are critical
to ensuring the quality, authenticity and safety of a
variety of foods we eat and products we use
• For example, high-value honey and high-end wines
are subject to mislabeling and adulteration
• NMR HoneyScreener ™and NMR WineScreener ™
can quantify very many ingredients in short, single
measurements, thereby ensuring purity and origin
© Bruker Corporation
Applied Markets & Pharma
13

14. EXAMPLE:
Next-Gen Semiconductor Metrology
• Mobility, cloud computing and big data demand
ever smaller and more powerful computer chips
• Chip & memory makers require next-gen nano-
metrology to ensure product yield and quality
• Bruker next-gen AFM and X-ray metrology tools
are essential for development and production at
advanced nodes and for new 3D chip structures
© Bruker Corporation
Nano-Analysis, Microscopy
& Materials Research
14

15. Clinical Research,
Microbiology & Diagnostics
© Bruker Corporation
EXAMPLE:
MALDI Biotyper & TissueTyper:
• Bruker has pioneered the MALDI Biotyper to ID
bacteria and yeasts more quickly and accurately
• Time-to-Result and expansive ID libraries are of
great clinical and economic value in microbiology
• Bruker has launched the MALDI TissueTyper for
clinical research in anatomical pathology & oncology
15

16. © Bruker Corporation
1. Company Overview
2. Profitable Growth Strategy
3. From Transformation to Operational Excellence
4. Financial Overview
Agenda
16

17. © Bruker Corporation
During our 3 year Transformation we made key changes to
our organization, systems & commercial capabilities
CommercialOrganization & Systems
-Reorganized; new leaders
-Clear performance metrics & incentives
-Integrated management processes
-Improving financial & ERP systems
-Applications-based marketing
-Reorganization of sales forces
-New CRM & sales management
-Improved pricing practices
17

18. © Bruker Corporation
In its Transformation, Bruker has executed important
initiatives to reduce costs and improve efficiency
Portfolio
Outsourcing/
Facilities Procurement IT Systems
Resource
Allocation
• Divested/shut
down unprofitable
product lines
• Bolt-on M&A:
preclinical imaging,
cell biology & X-Ray
semicon metrology
• Exited small plants
and streamlined
production
• Outsourcing
non-core
manufacturing
(on-going)
• Professionally
manage spending
to take advantage
of scale
• New management
reporting system
• Multi-year ERP
improvement
program underway
• Operating
spending well-
managed
• Reinvestment in
important
capabilities and
functions
18

19. © Bruker Corporation
We have continued to attract very experienced
senior managers and board members in H2 2015
SENIOR MANAGEMENT
Dr. René
Lenggenhager
President
BioSpin Group
PREVIOUS:
Mettler-Toledo
Dr. Dietrich
Hauffe
EVP Bruker Daltonics
Life Science Mass Spec
PREVIOUS:
Qiagen, Dionex
Christian
Busch
VP, Finance
BioSpin Group
PREVIOUS:
Novartis
John
Ornell
PREVIOUS:
CFO, Waters
Dr. Hermann
Requardt
PREVIOUS:
CEO, Siemens Healthcare
Dr. Robert
Rosenthal
CURRENT:
CEO, Taconic Biosciences
BOARD OF DIRECTORS
19

20. © Bruker Corporation
After 3 years of Transformation and Restructuring,
Bruker will now focus on Operational Excellence & Lean
2013 2014 2015 2016 2017 2018
Bruker BioSpin Bruker’s next Phase:
Operational Excellence
• Lean manufacturing
• Continued outsourcing
• Lean footprint
• Better business systems
• Commercial excellence
Bruker NANO
Bruker CALID
BEST
Outsourcing
Rightsizing
Rightsizing & Footprint Consolidation
Outsourcing
CAM Divestitures
Rightsizing & Footprint Consolidation
Outsourcing
Footprint Consolidation
20

21. © Bruker Corporation
1. Company Overview
2. Profitable Growth Strategy
3. From Transformation to Operational Excellence
4. Financial Overview
Agenda
21

22. © Bruker Corporation
Despite facing strong currency headwinds in each
of the past three years . . .
-$0.10
-$0.08
-$0.10
2013 2014 2015E
FX year-over-year effect on Non-GAAP EPS
22

23. © Bruker Corporation
. . .we are nonetheless delivering solid improvements in
our profitability and free cash flow
44.9%
46.1%
Non-GAAP
Gross Margin
9.3%
11.5%
Non-GAAP
Operating Margin
$0.46
$0.51
Non-GAAP
EPS
$18M
$57M
Free Cash Flow
+120 bps +220 bps +11% +$39M
Q3-14 YTD Q3-15 YTD
23

24. © Bruker Corporation
We have made good progress in improving
our working capital efficiency
$832m
$633m
0.46
0.38
0.00
0.20
0.40
0.60
$-
$200
$400
$600
$800
$1,000
$1,200
$1,400
2012 2013 2014 Q3-15 YTD
Working Capital Working Capital to Revenue Ratio
24

25. © Bruker Corporation
Improved performance and a strong balance
sheet have enabled us to initiate a share buyback
• A two-year share
repurchase program of up
to $225M started in mid-
November 2015
SHARE BUYBACK PROGRAM
$87M
$161M
Net Cash
+85%
Q3 YTD 2014 Q3 YTD 2015
1.4%
5.0%
Free Cash Flow
as a % of Revenue
+3.6%
25

26. © Bruker Corporation
We believe we have several years of meaningful margin
expansion opportunity ahead of us
10.2%
~11.7%*
2014 2015E 2016 2017 2018 2019 2020
Bruker Non-GAAP
Operating Margins
2016–2020
continue to close gap with peers
26
*FY15 guidance for operating margin expansion 150 basis point or more

27. © Bruker Corporation
Key Messages in 2016
1 Bruker is a differentiated leader
in attractive life science and
diagnostics tools markets, and
our brand stands for innovation
2 We focus on profitable growth in
four strategic growth areas
3 We will drive margin expansion
and cash flow as we transition
from Transformation to our next
phase of Operational Excellence
27

28. © Bruker Corporation
www.bruker.com
28